DK3743420T3 - Heterocyclylamino-substituerede triazoler som modulatorer af rho-associeret proteinkinase - Google Patents

Heterocyclylamino-substituerede triazoler som modulatorer af rho-associeret proteinkinase Download PDF

Info

Publication number
DK3743420T3
DK3743420T3 DK19702694.1T DK19702694T DK3743420T3 DK 3743420 T3 DK3743420 T3 DK 3743420T3 DK 19702694 T DK19702694 T DK 19702694T DK 3743420 T3 DK3743420 T3 DK 3743420T3
Authority
DK
Denmark
Prior art keywords
kinaches
heterocyclylamino
rho
modulators
associated protein
Prior art date
Application number
DK19702694.1T
Other languages
English (en)
Inventor
Clifford D Jones
Peter Bunyard
Gary Pitt
Liam Byrne
Thomas Pesnot
Nicolas E S Guisot
Original Assignee
Redx Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redx Pharma Plc filed Critical Redx Pharma Plc
Application granted granted Critical
Publication of DK3743420T3 publication Critical patent/DK3743420T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK19702694.1T 2018-01-25 2019-01-25 Heterocyclylamino-substituerede triazoler som modulatorer af rho-associeret proteinkinase DK3743420T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1801226.0A GB201801226D0 (en) 2018-01-25 2018-01-25 Modulators of Rho-associated protein kinase
PCT/GB2019/050215 WO2019145729A1 (en) 2018-01-25 2019-01-25 Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase

Publications (1)

Publication Number Publication Date
DK3743420T3 true DK3743420T3 (da) 2022-03-07

Family

ID=61558335

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19702694.1T DK3743420T3 (da) 2018-01-25 2019-01-25 Heterocyclylamino-substituerede triazoler som modulatorer af rho-associeret proteinkinase

Country Status (25)

Country Link
US (3) US11497751B2 (da)
EP (2) EP3743420B1 (da)
JP (2) JP7518324B2 (da)
KR (1) KR20200113216A (da)
CN (1) CN111655681B (da)
AU (1) AU2019213214B2 (da)
BR (1) BR112020013759A2 (da)
CA (1) CA3088330A1 (da)
CY (1) CY1125017T1 (da)
DK (1) DK3743420T3 (da)
EA (1) EA202091711A1 (da)
ES (1) ES2907833T3 (da)
GB (1) GB201801226D0 (da)
HR (1) HRP20220269T8 (da)
HU (1) HUE058940T2 (da)
IL (1) IL275988B2 (da)
LT (1) LT3743420T (da)
MX (1) MX2020007898A (da)
PH (1) PH12020550986A1 (da)
PL (1) PL3743420T3 (da)
PT (1) PT3743420T (da)
SG (1) SG11202006087UA (da)
SI (1) SI3743420T1 (da)
WO (1) WO2019145729A1 (da)
ZA (1) ZA202003983B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201801226D0 (en) 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase
CN111718310B (zh) * 2019-08-19 2021-06-11 中国药科大学 苯基取代的五元杂环类化合物及其制备方法、用途和药物组合物
CN110845410B (zh) * 2019-10-29 2021-02-26 暨明医药科技(苏州)有限公司 一种一锅法制备6,7-二甲氧基-3,4-二氢异喹啉盐酸盐的方法
IL310209A (en) * 2021-07-26 2024-03-01 Harvard College ROCK2 inhibitors and their uses
CN113999211B (zh) * 2021-11-23 2022-11-29 郑州大学 一类特异性抗前列腺癌活性的含1,2,3-三氮唑的吲唑骨架衍生物
GB202200735D0 (en) * 2022-01-20 2022-03-09 Redx Pharma Plc Compounds
WO2023182856A1 (ko) * 2022-03-24 2023-09-28 서울대학교산학협력단 로-키나제 억제제를 포함하는 켈로이드 등 피부 섬유화 질환의 예방 또는 치료용 약학적 조성물 및 그의 용도
CN115124558B (zh) * 2022-07-08 2024-08-13 闽都创新实验室 一种芳基硼酸酯类化合物的制备方法及其应用
WO2024123129A1 (ko) * 2022-12-08 2024-06-13 한국과학기술원 파브리병의 예방 또는 치료용 조성물
CN116891460A (zh) * 2023-07-12 2023-10-17 浙江大学 一种吲唑类衍生物或其药用盐及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9207396D0 (en) 1992-04-03 1992-05-13 Merck Sharp & Dohme Therapeutic agents
CN100355750C (zh) * 2000-09-15 2007-12-19 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吡唑化合物
CL2003002353A1 (es) * 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
WO2004052280A2 (en) * 2002-12-10 2004-06-24 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
US20050288347A1 (en) * 2004-03-26 2005-12-29 Hodge Carl N Certain triazole-based compounds, compositions, and uses thereof
WO2006135383A2 (en) * 2004-08-04 2006-12-21 Myriad Genetics, Inc. Indazoles
EP2035396B1 (en) 2006-05-25 2014-05-14 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
DE102007022565A1 (de) * 2007-05-14 2008-11-20 Merck Patent Gmbh Heterocyclische Indazolderivate
US8344144B2 (en) * 2008-06-18 2013-01-01 Merck Sharp & Dohme Corp. Inhibitors of Janus kinases
EP2550266B1 (en) * 2010-03-24 2018-05-09 Amitech Therapeutics Solutions, Inc. Heterocyclic compounds useful for kinase inhibition
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012084704A1 (en) * 2010-12-20 2012-06-28 Merck Serono S.A. Indazolyl triazole derivatives as irak inhibitors
US20150011751A1 (en) * 2012-03-09 2015-01-08 Carna Biosciences, Inc. Novel triazine derivative
EP3262041A4 (en) 2015-02-27 2018-08-01 Lycera Corporation Indazolyl thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease
CN114591242A (zh) 2015-12-16 2022-06-07 洛克索肿瘤学股份有限公司 可用作激酶抑制剂的化合物
CN110582491B (zh) * 2017-06-30 2023-09-29 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
GB201801226D0 (en) 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase

Also Published As

Publication number Publication date
WO2019145729A1 (en) 2019-08-01
BR112020013759A2 (pt) 2020-12-01
WO2019145729A9 (en) 2020-07-30
IL275988B2 (en) 2023-07-01
EP3743420A1 (en) 2020-12-02
SI3743420T1 (sl) 2022-06-30
PT3743420T (pt) 2022-02-04
HRP20220269T8 (hr) 2022-12-09
US20210038606A1 (en) 2021-02-11
CN111655681B (zh) 2024-01-05
US20240216386A1 (en) 2024-07-04
EA202091711A1 (ru) 2020-10-20
PL3743420T3 (pl) 2022-03-21
SG11202006087UA (en) 2020-08-28
KR20200113216A (ko) 2020-10-06
CA3088330A1 (en) 2019-08-01
US20230021916A1 (en) 2023-01-26
GB201801226D0 (en) 2018-03-14
CN111655681A (zh) 2020-09-11
EP4026834A1 (en) 2022-07-13
LT3743420T (lt) 2022-02-25
HRP20220269T1 (hr) 2022-05-13
US11497751B2 (en) 2022-11-15
ES2907833T3 (es) 2022-04-26
JP7518324B2 (ja) 2024-07-18
CY1125017T1 (el) 2023-03-24
IL275988B1 (en) 2023-03-01
EP3743420B1 (en) 2021-12-15
AU2019213214B2 (en) 2023-06-29
ZA202003983B (en) 2023-07-26
US11878020B2 (en) 2024-01-23
IL275988A (en) 2020-08-31
JP2024026193A (ja) 2024-02-28
MX2020007898A (es) 2020-09-07
HUE058940T2 (hu) 2022-09-28
JP2021512158A (ja) 2021-05-13
PH12020550986A1 (en) 2021-03-22
AU2019213214A1 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
DK3743420T3 (da) Heterocyclylamino-substituerede triazoler som modulatorer af rho-associeret proteinkinase
DK3774791T3 (da) Heterocykliske forbindelser som immunmodulatorer
DK3788040T3 (da) Pyridazinoner som parp7-inhibitorer
DK3684767T3 (da) Heterocykliske forbindelser som pad-inhibitorer
DK3704120T3 (da) Heterocykliske forbindelser som prmt5-inhibitorer
DK3442980T3 (da) Heterocykliske forbindelser som ret-kinase-hæmmere
DK3572416T3 (da) Diaryl-makrocykler som modulatorer af proteinkinaser
MA49908A (fr) Composés inhibant la protéine mcl-1
DK3724190T3 (da) Substituerede bicykliske heterocykliske forbindelser som PRMT5 inhibitorer
DK3743406T3 (da) Tmem16a modulatorer
DK3466934T3 (da) Sulfonamidforbindelser eller salt deraf som ribonukleotidreductase-inhibitorer til behandling af kræft
DK3288405T3 (da) Kemisk minimeret system til tidsreduceret påsætning af øjenvippeforlængelser
DK3512857T3 (da) Spiro-bicykliske inhibitorer af menin-mll-interaktion
DK3157929T3 (da) Pyrazolforbindelser som modulatorer af fshr og anvendelser deraf
DK3749669T3 (da) Ahr-modulatorer
MA50174A (fr) Formules de protéines de fusion vegfr-fc
DK3670499T3 (da) Pyrazolderivater, der er anvendelige som inhibitorer af 5-lipoxygenase-aktiverende protein (flap)
DK3414517T3 (da) Holografisk karakterisering af proteinaggregater
DK3551188T3 (da) Substituerede quinazolinsulfonamider som hæmmere af thioredoxin-interagerende protein (txnip)
DK3280407T3 (da) Anvendelse af isothiocyanatderivater som modulatorer af perifere og neuropatiske smerter
ES1224261Y (es) Aplicador de liquidos
UA39602S (uk) Комплект етикеток
DK3638686T3 (da) Peptidylketoamider som inhibitorer af rombeformede proteaser
UA38661S (uk) Комплект етикеток
UA39416S (uk) Комплект етикеток